IV = Intravenous, SC = Subcutaneous
Safety Data Sheets:
AAAAI
American Academy of Allergy Asthma & Immunology
AE
Adverse event
Ang2
Angiopoietin-2
ARR
Annualized Relapse Rate
ART
Assisted Reproductive Technology
ASTCT
American Society for Transplantation and Cellular Therapy
ATG
Anti-thymocyte globulin
CAR
Chimeric antigen receptor
CD3
Cluster of differentiation 3
CD4
Cluster of differentiation 4
CD8
Cluster of differentiation 8
CD19
Cluster of differentiation 19
CD20
Cluster of differentiation 20
CD226
Cluster of differentiation 226
CDC
Centers for Disease Control and Prevention
CI
Confidence Interval
CPAP
Continuous positive airway pressure
CR
Complete response
CRP
C-reactive protein
CRS
Cytokine release syndrome
CT
Computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
DIC
Disseminated intravascular coagulation
DLBCL
Diffuse large B-cell lymphoma
DMT
Disease-modifying therapy
DMT
Disease-modifying treatment
DoCR
Duration of complete response
DoR
Duration of response
DBPCFC
Double-blind, placebo-controlled food challenge
ECOG PS
Eastern Cooperative Oncology Group performance status
ECTRIMS
European Committee for Treatment and Research in Multiple Sclerosis
EDSS
Expanded Disability Status Scale
EMA
European Medicines Association
FAERS
FDA Adverse Event Reporting System
FDA
Food and Drug Administration
FDA
US Food and Drug Administration
FL
Follicular lymphoma
HCP
Health Care Provider
HGBCL
High-grade B-cell lymphoma
HLH
Hemophagocytic lymphohistiocytosis
ICANS
Immune effector cell-associated neurotoxicity syndrome
ICU
Intensive care unit
Ig
Immunoglobulin
IgE
Immunoglobulin E
IgG1
Immunoglobulin G1
INR
International normalized ratio
IRC
Independent Review Committee
ITIM
Immunoreceptor tyrosine-based inhibitory motif
LLN
Lower limit of normal
LMP
last menstrual cycle
LMP
Last menstrual period
MAS
Macrophage activation syndrome
MCA
Major congenital anomalies
MHC
Major histocompatibility complex
MS
Multiple sclerosis
MSKCC
Memorial Sloan Kettering Cancer Center
NK
Natural killer
NO
Nitric oxide
NOS
Not otherwise specified
OB/Gyn
Obstetrics and Gynecology
OCR
OCREVUS (ocrelizumab)
OR
Odds ratio
ORR
Objective response rate
PD-1
Programmed cell death protein 1
PD-L1
Programmed death-ligand 1
PET
Positron emission tomography
PFS
Progression-free survival
PMBCL
Primary mediastinal B-cell lymphoma
PML
progressive multifocal leukoencephalopathy
PPMS
Primary progressive multiple sclerosis
PTT
Partial thromboplastin time
PVR
Poliovirus receptor
RID
Relative infant dose
RMS
Relapsing multiple sclerosis
RRMS
Relapsing-remitting multiple sclerosis
SAE
Serious adverse event
T
Trimester
TCR
T-cell receptor
TIGIT
T cell immunoreceptor with Ig and ITIM domains
UCSF
University of California San Francisco
USPI
United States Prescribing Information
URTI
Upper respiratory tract infection
UTI
Urinary tract infection
VWF
von Wilebrand factor
NIH
National Institutes of Health
The link you have selected will take you to Genentech Clinical Trials, a different site also maintained by Genentech Medical Affairs.
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
Ab: antibody
AE: adverse event
ASTCT: American Society for Transplantation and Cellular Therapy
CR: complete response
CRS: cytokine release syndrome
CT: computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DoR: duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: follicular lymphoma
ICANS: immune effector cell-associated neurotoxicity syndrome
IRF: independent review facility
IV: intravenous
IQR: interquartile range
NCI CTCAE: National Center Institute Common Terminology Criteria for Adverse Events
NHL: non-Hodgkin lymphoma
ORR: objective response rate
PET: positron emission tomography
PFS: progression-free survival
PR: partial response
R/R: relapsed/refractory
SAE: serious adverse event
SD: stable disease
USPI: United States Prescribing Information
UTI: urinary tract infection
DBPCFC: Double-blind, placebo-controlled food challenge
FDA: Food and Drug Administration
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
IgE: Immunoglobulin E
NIH: National Institutes of Health
OIT: Oral immunotherapy
OLE: Open-label extension
R: Randomized
CD19: Cluster of differentiation 19
CD20: Cluster of differentiation 20
CDC: Centers for Disease Control and Prevention
COVID-19: Coronavirus disease of 2019
DMT: Disease-modifying therapy
ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
EMA: European Medicines Association
FDA: Food and Drug Administration
IgG1: Immunoglobulin G1
LMP: Last menstrual period
mAb: Monoclonal antibody
MCA: Major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
RID: Relative infant dose
UCSF: University of California San Francisco
URTI: Upper respiratory tract infection
UTI: Urinary tract infection
ASTCT: American Society for Transplantation and Cellular Therapy
CD20: Cluster of differentiation 20
CR: Complete response
CRS: Cytokine release syndrome
CT: Computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DLBCL: Diffuse large B-cell lymphoma
DoCR: Duration of complete response
DoR: Duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: Follicular lymphoma
HGBCL: High-grade B-cell lymphoma
ICANS: Immune effector cell-associated neurotoxicity syndrome
IRC: Independent Review Committee
NOS: Not otherwise specified
ORR: Objective response rate
PET: Positron emission tomography
PMBCL: Primary mediastinal B-cell lymphoma
AE: Adverse event
Ang2: Angiopoietin-2
ASTCT: American Society for Transplantation and Cellular Therapy
ATG: Anti-thymocyte globulin
CAR: Chimeric antigen receptor
CARTOX: CAR T-cell Therapy-Associated Toxicity
CD3: Cluster of differentiation 3
CPAP: Continuous positive airway pressure
CRP: C-reactive protein
CRS: Cytokine release syndrome
CTCAE: Common Terminology Criteria for Adverse Events
DIC: Disseminated intravascular coagulation
HLH: Hemophagocytic lymphohistiocytosis
ICANS: Immune effector cell–associated neurotoxicity syndrome
ICU: Intensive care unit
IFN-γ: Interferon-gamma
IL: Interleukin
INR: International normalized ratio
IRR: Infusion-related reaction
MAS: Macrophage activation syndrome
MSKCC: Memorial Sloan Kettering Cancer Center
NO: Nitric oxide
PTT: Partial thromboplastin time
TNF-α: Tumor necrosis factor alpha
VWF: von Wilebrand factor
CD3: Cluster of differentiation 3
TCR: T-cell receptor
CD4: Cluster of differentiation 4
CD8: Cluster of differentiation 8
CD226: Cluster of differentiation 226
Ig: Immunoglobulin
ITIM: Immunoreceptor tyrosine-based inhibitory motif
MHC: Major histocompatibility complex
NK: Natural killer
PD-1: Programmed cell death protein 1
PD-L1: Programmed death-ligand 1
PVR: Poliovirus receptor
TIGIT: T-cell immunoreceptor with Ig and ITIM domains
ARR: Annualized Relapse Rate
ART: Assisted Reproductive Technology
CI: Confidence Interval
DMT: Disease-modifying therapy
EDSS: Expanded Disability Status Scale
MS: Multiple Sclerosis
T: Trimester
OR: Odds ratio
OB/Gyn: Obstetrics and Gynecology
AAAAI: American Academy of Allergy Asthma & Immunology
DMT: Disease-modifying therapy
HCP: Health Care Provider
Ig: Immunoglobulin
LLN: Lower limit of normal
MS: Multiple Sclerosis
NK: Natural killer
FAERS: FDA Adverse Event Reporting System
FDA: US Food and Drug Administration
Ig: Immunoglobulin
LMP: last menstrual cycle
MCA: major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
PML: progressive multifocal leukoencephalopathy
PPMS: Primary progressive multiple sclerosis
RMS: Relapsing multiple sclerosis